1887

Abstract

At present, few data are available on the prevalence and antifungal susceptibility of complex isolates from HIV-infected individuals. The complex comprises three species, , and . Fifteen of 318 isolates were identified as members of the complex by PCR and restriction fragment length polymorphism (RFLP). The prevalence of complex isolates was 4.7 %, 2.2 % being identified as and 2.5 % as , while no was isolated. This is believed to be the first study that has identified isolates of obtained from the oral cavity of HIV-infected individuals. Antifungal susceptibility tests indicated that all the isolates were susceptible to amphotericin B (AMB), fluconazole (FLC), ketoconazole (KTC), itraconazole (ITC), voriconazole (VRC) and caspofungin (CASPO). Although isolates of and were susceptible to FLC, isolates of showed a tendency for higher MICs (≥1.0 µg ml). Based upon the frequency of candidiasis and the fact that certain isolates of the complex respond differently to FLC therapy, our data may be of therapeutic relevance with respect to susceptibility and potential resistance to specific antifungal agents. Our data suggest that can be a human commensal; its importance as a pathogen has yet to be confirmed.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.045112-0
2012-12-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/12/1758.html?itemId=/content/journal/jmm/10.1099/jmm.0.045112-0&mimeType=html&fmt=ahah

References

  1. Almirante B., Rodríguez D., Cuenca-Estrella M., Almela M., Sanchez F., Ayats J., Alonso-Tarres C., Rodriguez-Tudela J. L., Pahissa A. 2006; Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 44:1681–1685 [View Article][PubMed]
    [Google Scholar]
  2. Bonfietti L. X., Martins M. A., Szeszs M. W., Pukiskas S. B., Purisco S. U., Pimentel F. C., Pereira G. H., Silva D. C., Oliveira L., Melhem M. S. 2012; Prevalence, distribution and antifungal susceptibility profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis bloodstream isolates. J Med Microbiol 61:1003–1008 [View Article][PubMed]
    [Google Scholar]
  3. de Toro M., Torres M. J., Maite R., Aznar J. 2011; Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect 17:418–424 [View Article][PubMed]
    [Google Scholar]
  4. Enger L., Joly S., Pujol C., Simonson P., Pfaller M., Soll D. R. 2001; Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis . J Clin Microbiol 39:658–669 [View Article][PubMed]
    [Google Scholar]
  5. EUCAST 2008a; EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14:398–405 [View Article][PubMed]
    [Google Scholar]
  6. EUCAST 2008b; EUCAST technical note on fluconazole. Clin Microbiol Infect 14:193–195[PubMed] [CrossRef]
    [Google Scholar]
  7. EUCAST 2008c). EUCAST Technical Note on voriconazole. Clin Microbiol Infect 14:985–987 [View Article][PubMed]
    [Google Scholar]
  8. Garcia-Effron G., Katiyar S. K., Park S., Edlind T. D., Perlin D. S. 2008; A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52:2305–2312 [View Article][PubMed]
    [Google Scholar]
  9. Ghannoum M. A., Jurevic R. J., Mukherjee P. K., Cui F., Sikaroodi M., Naqvi A., Gillevet P. M. 2010; Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog 6:e1000713 [View Article][PubMed]
    [Google Scholar]
  10. Gomez-Lopez A., Alastruey-Izquierdo A., Rodriguez D., Almirante B., Pahissa A., Rodriguez-Tudela J. L., Cuenca-Estrella M. Barcelona Candidemia Project Study Group 2008; Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 52:1506–1509 [View Article][PubMed]
    [Google Scholar]
  11. Gonçalves S. S., Amorim C. S., Nucci M., Padovan A. C., Briones M. R., Melo A. S., Colombo A. L. 2010; Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 16:885–887[PubMed] [CrossRef]
    [Google Scholar]
  12. Hensgens L. A., Tavanti A., Mogavero S., Ghelardi E., Senesi S. 2009; AFLP genotyping of Candida metapsilosis clinical isolates: evidence for recombination. Fungal Genet Biol 46:750–758 [View Article][PubMed]
    [Google Scholar]
  13. Iida S., Imai T., Oguri T., Okuzumi K., Yamanaka A., Moretti-Branchini M. L., Nishimura K., Mikami Y. 2005; Genetic diversity of the internal transcribed spacers (ITS) and 5.8S rRNA genes among the clinical isolates of Candida parapsilosis in Brazil and Japan. Nippon Ishinkin Gakkai Zasshi 46:133–137 [View Article][PubMed]
    [Google Scholar]
  14. Kocsubé S., Tóth M., Vágvölgyi C., Dóczi I., Pesti M., Pócsi I., Szabó J., Varga J. 2007; Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol 56:190–195 [View Article][PubMed]
    [Google Scholar]
  15. Kurtzman C. P. K., Fell J. W. 1998 The Yeasts: a Taxonomic Study. Amsterdam NY: Elsevier Science Publishers;
    [Google Scholar]
  16. Lasker B. A., Butler G., Lott T. J. 2006; Molecular genotyping of Candida parapsilosis group I clinical isolates by analysis of polymorphic microsatellite markers. J Clin Microbiol 44:750–759 [View Article][PubMed]
    [Google Scholar]
  17. Legout L., Assal M., Rohner P., Lew D., Bernard L., Hoffmeyer P. 2006; Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis 38:728–730 [View Article][PubMed]
    [Google Scholar]
  18. Lehmann P. F., Lin D., Lasker B. A. 1992; Genotypic identification and characterization of species and strains within the genus Candida by using random amplified polymorphic DNA. J Clin Microbiol 30:3249–3254[PubMed]
    [Google Scholar]
  19. Lin D., Wu L. C., Rinaldi M. G., Lehmann P. F. 1995; Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 33:1815–1821[PubMed]
    [Google Scholar]
  20. Lockhart S. R., Messer S. A., Pfaller M. A., Diekema D. J. 2008; Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis . J Clin Microbiol 46:2659–2664 [View Article][PubMed]
    [Google Scholar]
  21. Moris D. V., Melhem M. S. C., Martins M. A., Mendes R. P. 2008; Oral Candida spp. colonization in human immunodeficiency virus-infected individuals. J Venom Anim Toxins incl Trop Dis 14:224–257 [View Article]
    [Google Scholar]
  22. Odds F. C., Hanson M. F., Davidson A. D., Jacobsen M. D., Wright P., Whyte J. A., Gow N. A., Jones B. L. 2007; One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 56:1066–1075 [View Article][PubMed]
    [Google Scholar]
  23. Pemán J., Cantón E., Gobernado M. the Spanish ECMM Working Group on Candidaemia 2005; Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24:23–30 [View Article][PubMed]
    [Google Scholar]
  24. Pfaller M. A., Diekema D. J. 2002; Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 40:3551–3557 [View Article][PubMed]
    [Google Scholar]
  25. Pfaller M. A., Diekema D. J. 2007; Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163 [View Article][PubMed]
    [Google Scholar]
  26. Pfaller M. A., Diekema D. J., Gibbs D. L., Newell V. A., Ng K. P., Colombo A. L., Finquelievich J., Barnes R., Wadula J. Global Antifungal Surveillance Group 2008; Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46:842–849 [View Article][PubMed]
    [Google Scholar]
  27. Rodríguez-Tudela J. L., Arendrup M. C., Cuenca-Estrella M., Donnelly J. P., Lass-Flörl C. 2010; EUCAST breakpoints for antifungals. Drug News Perspect 23:93–97 [View Article][PubMed]
    [Google Scholar]
  28. Sambrook J., Fritsch E. F., Maniatis T. 1989 Molecular Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  29. Sarvikivi E., Lyytikäinen O., Soll D. R., Pujol C., Pfaller M. A., Richardson M., Koukila-Kähkölä P., Luukkainen P., Saxén H. 2005; Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 43:2729–2735 [View Article][PubMed]
    [Google Scholar]
  30. Silva A. P., Miranda I. M., Lisboa C., Pina-Vaz C., Rodrigues A. G. 2009; Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 47:2392–2397 [View Article][PubMed]
    [Google Scholar]
  31. Soll D. R. 2000; The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev 13:332–370 [View Article][PubMed]
    [Google Scholar]
  32. Tavanti A., Davidson A. D., Gow N. A., Maiden M. C. J., Odds F. C. 2005; Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292 [View Article][PubMed]
    [Google Scholar]
  33. Tavanti A., Hensgens L. A., Ghelardi E., Campa M., Senesi S. 2007; Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 45:1455–1462 [View Article][PubMed]
    [Google Scholar]
  34. Tay S. T., Na S. L., Chong J. 2009; Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol 58:185–191 [View Article][PubMed]
    [Google Scholar]
  35. Trofa D., Gácser A., Nosanchuk J. D. 2008; Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 21:606–625 [View Article][PubMed]
    [Google Scholar]
  36. van Asbeck E., Clemons K. V., Martinez M., Tong A. J., Stevens D. A. 2008; Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 62:106–109 [View Article][PubMed]
    [Google Scholar]
  37. Vargas K. G., Joly S. 2002; Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol 40:341–350 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.045112-0
Loading
/content/journal/jmm/10.1099/jmm.0.045112-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error